<strong>Objective</strong>: Exploring the expression characteristics of CRP/ALB (CAR) in DLBCL patients and its value in prognostic judgment. <strong>Methods:</strong> We collected the basic in...<strong>Objective</strong>: Exploring the expression characteristics of CRP/ALB (CAR) in DLBCL patients and its value in prognostic judgment. <strong>Methods:</strong> We collected the basic information, clinical characteristics, laboratory examinations and follow-up prognosis of 142 newly diagnosed DLBCL patients with relatively complete data in our hospital and performed statistical analysis. We used X-tile analysis software to obtain the best cut-off value of CAR (0.33), compared the clinical characteristics and survival of patients in the high CAR group and the low CAR group, and compared the survival status with the IPI scoring system. <strong>Results:</strong> 1) There were significant differences in staging, grouping, IPI scores, extranodal involvement, LDH levels, <em>β</em>2-microglobulin, CA125, and Hb levels between the high CAR group and the low CAR group (all <em>P</em> < 0.05). 2) According to the survival curve, the OS of the high CAR group was significantly shorter than that of the low CAR group (<em>P</em> < 0.01), and the one-year, three-year and five-year survival conditions of high CAR group were all shorter than those of low CAR group. 3) COX analysis showed that high CAR is an independent poor prognostic factor for DLBCL patients. 4) A comparative analysis of OS, three-year and five-year survival showed that the combination of CAR and IPI was significantly better than the IPI system, and there was no significant difference in the evaluation value of the prognosis between CAR alone and IPI alone. <strong>Conclusion:</strong> High CAR value, like the IPI scoring system, is an independent poor prognostic factor of DLBCL, can be used as a reliable indicator of prognosis. And CAR can also be combined with IPI to evaluate the prognosis of DLBCL, of which the effect is better than that of IPI alone.展开更多
目的探讨在接受一线使用PD-1/PD-L1抑制剂联合化疗治疗前C反应蛋白与白蛋白比值(C-reactive protein to serum albumin ratio,CRP/Alb)、泛免疫炎症值(pan-immune-inflammation value,PIV)在晚期非小细胞肺癌(non-small cell lung cance...目的探讨在接受一线使用PD-1/PD-L1抑制剂联合化疗治疗前C反应蛋白与白蛋白比值(C-reactive protein to serum albumin ratio,CRP/Alb)、泛免疫炎症值(pan-immune-inflammation value,PIV)在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后中的评估价值。方法回顾性分析2018年11月~2021年12月在徐州医科大学附属医院确诊为晚期NSCLC一线使用PD-1/PD-L1抑制剂联合化疗方案治疗的85例患者的临床资料,采用受试者工作特征(receiver operator characteristic,ROC)曲线分析确定CRP/Alb、PIV的最佳截断值,COX比例风险回归模型进行单因素和多因素分析。结果本研究共纳入85例晚期NSCLC患者,CRP/Alb的最佳截断值为0.38,高、低CRP/Alb组晚期NSCLC患者在吸烟史、高血压病史方面比较,差异均有统计学意义(P均<0.05);PIV的最佳截断值为666.77,高、低PIV组晚期NSCLC患者在ECOG-PS评分方面比较,差异有统计学意义(P<0.05)。高CRP/Alb组和高PIV组患者的疾病控制率(disease control rate,DCR)和无进展生存期(progression-free survival,PFS)均较低CRP/Alb组和低PIV组有所降低,差异有统计学意义(P<0.05)。单因素和多因素COX回归分析结果显示,高CRP/Alb、高PIV是一线使用PD-1/PD-L1抑制剂联合化疗方案治疗晚期NSCLC患者PFS不良预后的预测因素。结论高CRP/Alb、高PIV与晚期NSCLC患者较差的PFS相关,其可能是晚期NSCLC患者一线免疫联合化疗方案治疗的潜在有价值的预后因素。展开更多
文摘<strong>Objective</strong>: Exploring the expression characteristics of CRP/ALB (CAR) in DLBCL patients and its value in prognostic judgment. <strong>Methods:</strong> We collected the basic information, clinical characteristics, laboratory examinations and follow-up prognosis of 142 newly diagnosed DLBCL patients with relatively complete data in our hospital and performed statistical analysis. We used X-tile analysis software to obtain the best cut-off value of CAR (0.33), compared the clinical characteristics and survival of patients in the high CAR group and the low CAR group, and compared the survival status with the IPI scoring system. <strong>Results:</strong> 1) There were significant differences in staging, grouping, IPI scores, extranodal involvement, LDH levels, <em>β</em>2-microglobulin, CA125, and Hb levels between the high CAR group and the low CAR group (all <em>P</em> < 0.05). 2) According to the survival curve, the OS of the high CAR group was significantly shorter than that of the low CAR group (<em>P</em> < 0.01), and the one-year, three-year and five-year survival conditions of high CAR group were all shorter than those of low CAR group. 3) COX analysis showed that high CAR is an independent poor prognostic factor for DLBCL patients. 4) A comparative analysis of OS, three-year and five-year survival showed that the combination of CAR and IPI was significantly better than the IPI system, and there was no significant difference in the evaluation value of the prognosis between CAR alone and IPI alone. <strong>Conclusion:</strong> High CAR value, like the IPI scoring system, is an independent poor prognostic factor of DLBCL, can be used as a reliable indicator of prognosis. And CAR can also be combined with IPI to evaluate the prognosis of DLBCL, of which the effect is better than that of IPI alone.
文摘目的探讨在接受一线使用PD-1/PD-L1抑制剂联合化疗治疗前C反应蛋白与白蛋白比值(C-reactive protein to serum albumin ratio,CRP/Alb)、泛免疫炎症值(pan-immune-inflammation value,PIV)在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后中的评估价值。方法回顾性分析2018年11月~2021年12月在徐州医科大学附属医院确诊为晚期NSCLC一线使用PD-1/PD-L1抑制剂联合化疗方案治疗的85例患者的临床资料,采用受试者工作特征(receiver operator characteristic,ROC)曲线分析确定CRP/Alb、PIV的最佳截断值,COX比例风险回归模型进行单因素和多因素分析。结果本研究共纳入85例晚期NSCLC患者,CRP/Alb的最佳截断值为0.38,高、低CRP/Alb组晚期NSCLC患者在吸烟史、高血压病史方面比较,差异均有统计学意义(P均<0.05);PIV的最佳截断值为666.77,高、低PIV组晚期NSCLC患者在ECOG-PS评分方面比较,差异有统计学意义(P<0.05)。高CRP/Alb组和高PIV组患者的疾病控制率(disease control rate,DCR)和无进展生存期(progression-free survival,PFS)均较低CRP/Alb组和低PIV组有所降低,差异有统计学意义(P<0.05)。单因素和多因素COX回归分析结果显示,高CRP/Alb、高PIV是一线使用PD-1/PD-L1抑制剂联合化疗方案治疗晚期NSCLC患者PFS不良预后的预测因素。结论高CRP/Alb、高PIV与晚期NSCLC患者较差的PFS相关,其可能是晚期NSCLC患者一线免疫联合化疗方案治疗的潜在有价值的预后因素。
